Patented branded drugs face a 100% tariff into the US under the Trump pharma policy — the single highest product-specific rate in the current US trade book. Generics, active pharmaceutical ingredients, and most medical devices stay duty-free. That bifurcation hits four countries hardest: Ireland (US imports roughly $50B in branded drugs in 2024), Switzerland ($23B), Germany ($14B), and India (the generics giant, mostly insulated). The Section 232 pharma investigation runs in parallel with the March 11 Section 301 capacity investigation and is expected to close before the July 24 Section 122 sunset. Here's what's actually in force, what's threatened, and what a 100% tariff does to a $1M Lipitor shipment from Cork.
What's Actually In Force vs. Threatened (April 2026)
In force right now: 10% Section 122 on every pharmaceutical import, applied uniformly. MFN base on chapter 30 is 0% under the WTO Pharmaceutical Tariff Elimination Agreement. Threatened and partially announced: a 100% tariff on patented branded drugs under Section 232 national security authority. Trump signaled the rate in 2025; the formal Section 232 investigation runs through 2026. The split: patented branded products pay 100%; off-patent generics stay at 0% MFN plus 10% Section 122 = 10% total. The administration's stated rationale is reshoring — Ireland and Switzerland host the largest US-bound branded drug capacity, and Trump wants both moved to US soil.
Why Pharma Has Been Duty-Free Since 1995
The WTO Pharmaceutical Tariff Elimination Agreement of 1995 — signed by the US, EU, Japan, Switzerland, and others — eliminated MFN duty on roughly 7,000 pharmaceutical products in chapter 30. The Section 122 layer added 10% in February 2026 — the first US import duty on pharma in 30+ years. A 100% Section 232 layer on top would be the biggest reversal since the agreement was signed. The legal authority works because Section 232 supersedes the WTO commitment when invoked on national security grounds.
Worked Example: $1M Branded Drug Shipment from Ireland
A $1,000,000 CIF shipment of patented Lipitor from a Pfizer facility in Cork, Ireland, classified under HTS 3004.90 (other medicaments, retail-packaged). MFN: 0%. Section 122 at 10% = $100,000. If the threatened Section 232 patented-pharma rate of 100% lands: $1,000,000. MPF at 0.3464% = $3,464 (capped at $634.62 per entry). HMF at 0.125% = $1,250. Total duty under the threatened structure: roughly $1,101,250. Effective rate: 110%. That's not a typo — patented pharma would carry the highest single-product effective rate in US trade. Today, before the Section 232 lands, the same shipment pays $101,250 in duty (effectively 10%). The delta between pre- and post-Section 232 on a $1M Irish shipment is $1,000,000 of new duty per container.
Generics, APIs, and Medical Devices Stay Different
Generic drugs pay 10% Section 122 on top of 0% MFN — total 10%. The 100% rate is patent-specific. Active pharmaceutical ingredients (APIs, HTS 2941 and 2942) pay 10% Section 122 plus 0% MFN — same as generics. Medical devices (chapter 90) are excluded from chapter 30 and have their own MFN structure: most diagnostic equipment is 0%, surgical instruments 0%, dental equipment 0-2%. So the 100% threat does not hit Indian generic exporters (Cipla, Dr. Reddy's, Sun Pharma), it does not hit Chinese API producers (Section 301's separate 25% Chinese layer applies, putting Chinese APIs at 35% combined), and it does not hit medical device makers in Ireland or Germany. The 100% rate is a precision instrument aimed at branded patent-holding manufacturers — primarily US firms producing offshore to capture Irish and Swiss tax treatment.
Country Exposure: Ireland, Switzerland, India, Germany
Ireland is the largest exposure: roughly $50B in pharma exports to the US in 2024, primarily branded patented drugs from Pfizer, Eli Lilly, AbbVie, Merck, and Johnson & Johnson facilities operating under Ireland's 12.5% corporate tax rate. Switzerland is second at $23B, dominated by Roche and Novartis. Germany at $14B, primarily Bayer and Boehringer Ingelheim. India is the largest source of generic dose volume but the dollar value sits around $9B — almost all generic, almost all staying at 10%. China runs ~$2.5B mostly in APIs (35% effective with Section 301). The 100% rate would hit Ireland and Switzerland hardest because their export mix is 90%+ branded patented product. India's generics-dominated mix barely moves.
The Section 232 Pharma Investigation Timeline
Commerce launched the Section 232 pharma investigation in 2025 under the same statutory framework that produced the steel, aluminum, copper, and semiconductor tariffs. Commerce must find that imports threaten national security; then the President has 90 days to decide on remedies. The administration's stated goal is finalizing the pharma determination before the Section 122 July 24 sunset so the product-specific rate lands before the 10% baseline expires. Realistic expectation: a determination by mid-July, with rates effective immediately or with a 30-day implementation window.
What This Does to US Drug Prices
A 100% tariff flows into US patient prices — eventually. Drug companies pay duty at the port (the importer is usually the US sales sub of the multinational), and the duty becomes a cost of goods. On patented drugs with no generic competition, pricing power is high — 70-90% pass-through to commercial insurers and patient out-of-pocket over 12-24 months. Medicare Part D and Medicaid pricing is partly constrained by IRA negotiations, but rebates work off list price, and list prices reset upward to absorb the duty. US branded drug spending runs about $400B a year; a 100% tariff on the imported share (~$95B) creates roughly $95B in new duty, of which $60-80B likely reaches patient prices. The administration's counter is reshoring — but reshoring a Pfizer Cork facility runs 5-7 years and tens of billions in capex. Duty hits 2026; reshoring offset arrives 2031 at the earliest.
What Importers Should Do This Week
Step 1: For any company importing branded patented drugs through a US sales sub, model 100% tariff scenarios on Q3 2026 forecasts — assume an August 1 effective date and back-load inventory before the rate lands. Step 2: For generic importers, stay at 10% Section 122 and monitor for any expansion of the 232 list to include generics (unlikely but politically possible). Step 3: For API buyers, the Section 301 investigation on China creates separate risk — Chinese APIs at 35% could move to 50%+ with the new determination. Step 4: Confirm patent status on every imported SKU. CBP will need a patented-vs-generic indicator on entry summaries once Section 232 lands. Step 5: For Irish and Swiss-sourced product, check whether re-routing as API imports through US finishing capacity drops the stack from 100% to 10% on the same molecule.
Key Takeaway
Trump's pharma tariff structure splits the world into two buckets: patented branded drugs at a threatened 100%, and generics, APIs, and medical devices at 10%. The Section 232 investigation closes before the July 24 Section 122 sunset, putting a high-probability rate change in mid-July. Ireland and Switzerland take the hardest hit; India's generics business stays insulated. US drug prices on imported branded products will absorb most of any duty, with 12-24 month pass-through to commercial patients and a longer lag through Medicare/Medicaid. Reshoring takes 5+ years; the duty hits 2026. Model 100% scenarios on every patented import line now, segregate generics from branded on entry summaries, and watch the Federal Register weekly for the Commerce Section 232 determination.
Calculate Your Import Duty
Get an instant estimate for your specific product, country, and shipment value.
Open Tariff Calculator